INCYPRO Asparaginase Program 

A long-acting asparaginase for the treatment of Acute Lymphoblastic Leukemia 

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. This hematologic malignancy affects both children and adults. Asparaginase is a key component of frontline treatment, yet current asparaginase-containing drugs face two major limitations:

Short half-life and frequent dosing 

  • Erwinia-derived asparaginase has a very short half-life 
  • Treatment schedules often require in-clinic dosing every 48 hours, which adds burden and increases healthcare costs.

Hypersensitivity reactions 

  • Most of the patients start with PEGylated asparaginase and must switch to a second asparaginase product due to hypersensitivity reactions 
  • Some patients experience “silent inactivation” with no obvious symptoms 

Our solution: INCYPRO-stabilized asparaginase

Incircular is developing a biobetter asparaginase candidate with best-in-class potential, stabilized using the proprietary INCYPRO platform. 

Approach
INCYPRO reinforces the 3D structure of asparaginase, minimizing unfolding and degradation. 

Design
Minimal sequence modification and unique structural design to preserve activity.

Solution
A long-acting asparaginase, with minimal hypersensitivity reactions and less frequent inpatient dosing, improving patients’ quality of life.

Preclinical results

  • Significant increase in elimination half-life
  • Sustained plasma asparagine depletion
  • No acute toxicity observed
    Contact Us

    Development status and next steps

    • Preclinical PoC completed
    • Scale-up and formulation development in progress
    • Seeking seed/Series A investment to reach Phase I by mid-2028